Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
Shirasawa M, Yoshida T, Takayanagi D, Shiraishi K, Yagishita S, Sekine K, Kanda S, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Hamada A, Kohno T, Yamamoto N, Watanabe SI, Ohe Y, Motoi N. Shirasawa M, et al. Among authors: motoi n. Clin Lung Cancer. 2021 Jul;22(4):282-291.e6. doi: 10.1016/j.cllc.2021.02.003. Epub 2021 Feb 8. Clin Lung Cancer. 2021. PMID: 33722498
[A clinical study of advanced large cell neuroendocrine carcinoma].
Kishi K, Homma S, Takaya H, Miyamoto A, Sakamoto S, Kurosaki A, Motoi N, Yoshimura K. Kishi K, et al. Among authors: motoi n. Nihon Kokyuki Gakkai Zasshi. 2006 Aug;44(8):556-60. Nihon Kokyuki Gakkai Zasshi. 2006. PMID: 16972612 Japanese.
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Horiike A, Takeuchi K, Uenami T, Kawano Y, Tanimoto A, Kaburaki K, Tambo Y, Kudo K, Yanagitani N, Ohyanagi F, Motoi N, Ishikawa Y, Horai T, Nishio M. Horiike A, et al. Among authors: motoi n. Lung Cancer. 2016 Mar;93:43-6. doi: 10.1016/j.lungcan.2015.12.011. Epub 2015 Dec 30. Lung Cancer. 2016. PMID: 26898613
Giant lamellar bodies associated with adenocarcinoma of the lung.
Shigenobu T, Motoi N, Asamura H, Watanabe SI, Hiraoka N, Yoshida A. Shigenobu T, et al. Among authors: motoi n. Histopathology. 2016 Dec;69(6):1090-1092. doi: 10.1111/his.13052. Epub 2016 Sep 27. Histopathology. 2016. PMID: 27482850 No abstract available.
Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern.
Masai K, Tsuta K, Motoi N, Shiraishi K, Furuta K, Suzuki S, Asakura K, Nakagawa K, Sakurai H, Watanabe SI, Hiraoka N, Asamura H. Masai K, et al. Among authors: motoi n. J Thorac Oncol. 2016 Dec;11(12):2141-2149. doi: 10.1016/j.jtho.2016.07.034. Epub 2016 Aug 27. J Thorac Oncol. 2016. PMID: 27575421 Free article.
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
Sakakibara R, Inamura K, Tambo Y, Ninomiya H, Kitazono S, Yanagitani N, Horiike A, Ohyanagi F, Matsuura Y, Nakao M, Mun M, Okumura S, Inase N, Nishio M, Motoi N, Ishikawa Y. Sakakibara R, et al. Among authors: motoi n. Clin Lung Cancer. 2017 Sep;18(5):527-534.e1. doi: 10.1016/j.cllc.2016.12.002. Epub 2016 Dec 22. Clin Lung Cancer. 2017. PMID: 28111119
Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.
Yoshida A, Kobayashi E, Kubo T, Kodaira M, Motoi T, Motoi N, Yonemori K, Ohe Y, Watanabe SI, Kawai A, Kohno T, Kishimoto H, Ichikawa H, Hiraoka N. Yoshida A, et al. Among authors: motoi t, motoi n. Mod Pathol. 2017 Jun;30(6):797-809. doi: 10.1038/modpathol.2017.11. Epub 2017 Mar 3. Mod Pathol. 2017. PMID: 28256572 Free article.
208 results